Literature DB >> 29713020

Pathway-based dissection of the genomic heterogeneity of cancer hallmarks' acquisition with SLAPenrich.

Francesco Iorio1,2,3, Luz Garcia-Alonso4,5, Jonathan S Brammeld6, Iňigo Martincorena6, David R Wille7,5, Ultan McDermott6, Julio Saez-Rodriguez8,9,10.   

Abstract

Cancer hallmarks are evolutionary traits required by a tumour to develop. While extensively characterised, the way these traits are achieved through the accumulation of somatic mutations in key biological pathways is not fully understood. To shed light on this subject, we characterised the landscape of pathway alterations associated with somatic mutations observed in 4,415 patients across ten cancer types, using 374 orthogonal pathway gene-sets mapped onto canonical cancer hallmarks. Towards this end, we developed SLAPenrich: a computational method based on population-level statistics, freely available as an open source R package. Assembling the identified pathway alterations into sets of hallmark signatures allowed us to connect somatic mutations to clinically interpretable cancer mechanisms. Further, we explored the heterogeneity of these signatures, in terms of ratio of altered pathways associated with each individual hallmark, assuming that this is reflective of the extent of selective advantage provided to the cancer type under consideration. Our analysis revealed the predominance of certain hallmarks in specific cancer types, thus suggesting different evolutionary trajectories across cancer lineages. Finally, although many pathway alteration enrichments are guided by somatic mutations in frequently altered high-confidence cancer genes, excluding these driver mutations preserves the hallmark heterogeneity signatures, thus the detected hallmarks' predominance across cancer types. As a consequence, we propose the hallmark signatures as a ground truth to characterise tails of infrequent genomic alterations and identify potential novel cancer driver genes and networks.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29713020      PMCID: PMC5928049          DOI: 10.1038/s41598-018-25076-6

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


  73 in total

1.  Guidelines for human gene nomenclature.

Authors:  Hester M Wain; Elspeth A Bruford; Ruth C Lovering; Michael J Lush; Mathew W Wright; Sue Povey
Journal:  Genomics       Date:  2002-04       Impact factor: 5.736

Review 2.  Emerging cytokine networks in colorectal cancer.

Authors:  Nathan R West; Sarah McCuaig; Fanny Franchini; Fiona Powrie
Journal:  Nat Rev Immunol       Date:  2015-09-11       Impact factor: 53.106

Review 3.  Matrix metalloproteinases and tumor metastasis.

Authors:  Elena I Deryugina; James P Quigley
Journal:  Cancer Metastasis Rev       Date:  2006-03       Impact factor: 9.264

Review 4.  Lessons from the cancer genome.

Authors:  Levi A Garraway; Eric S Lander
Journal:  Cell       Date:  2013-03-28       Impact factor: 41.582

5.  Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles.

Authors:  Aravind Subramanian; Pablo Tamayo; Vamsi K Mootha; Sayan Mukherjee; Benjamin L Ebert; Michael A Gillette; Amanda Paulovich; Scott L Pomeroy; Todd R Golub; Eric S Lander; Jill P Mesirov
Journal:  Proc Natl Acad Sci U S A       Date:  2005-09-30       Impact factor: 11.205

Review 6.  The cancer genome.

Authors:  Michael R Stratton; Peter J Campbell; P Andrew Futreal
Journal:  Nature       Date:  2009-04-09       Impact factor: 49.962

7.  Camera: a competitive gene set test accounting for inter-gene correlation.

Authors:  Di Wu; Gordon K Smyth
Journal:  Nucleic Acids Res       Date:  2012-05-25       Impact factor: 16.971

8.  Identifying cancer driver genes in tumor genome sequencing studies.

Authors:  Ahrim Youn; Richard Simon
Journal:  Bioinformatics       Date:  2010-12-17       Impact factor: 6.937

9.  COSMIC: exploring the world's knowledge of somatic mutations in human cancer.

Authors:  Simon A Forbes; David Beare; Prasad Gunasekaran; Kenric Leung; Nidhi Bindal; Harry Boutselakis; Minjie Ding; Sally Bamford; Charlotte Cole; Sari Ward; Chai Yin Kok; Mingming Jia; Tisham De; Jon W Teague; Michael R Stratton; Ultan McDermott; Peter J Campbell
Journal:  Nucleic Acids Res       Date:  2014-10-29       Impact factor: 16.971

10.  Functional impact bias reveals cancer drivers.

Authors:  Abel Gonzalez-Perez; Nuria Lopez-Bigas
Journal:  Nucleic Acids Res       Date:  2012-08-16       Impact factor: 16.971

View more
  9 in total

1.  Gastric Cancer Pre-Stage Detection and Early Diagnosis of Gastritis Using Serum Protein Signatures.

Authors:  Shahid Aziz; Faisal Rasheed; Rabaab Zahra; Simone König
Journal:  Molecules       Date:  2022-04-30       Impact factor: 4.927

2.  Comparative Molecular Life History of Spontaneous Canine and Human Gliomas.

Authors:  Samirkumar B Amin; Kevin J Anderson; C Elizabeth Boudreau; Emmanuel Martinez-Ledesma; Emre Kocakavuk; Kevin C Johnson; Floris P Barthel; Frederick S Varn; Cynthia Kassab; Xiaoyang Ling; Hoon Kim; Mary Barter; Ching C Lau; Chew Yee Ngan; Margaret Chapman; Jennifer W Koehler; James P Long; Andrew D Miller; C Ryan Miller; Brian F Porter; Daniel R Rissi; Christina Mazcko; Amy K LeBlanc; Peter J Dickinson; Rebecca A Packer; Amanda R Taylor; John H Rossmeisl; Kevin D Woolard; Amy B Heimberger; Jonathan M Levine; Roel G W Verhaak
Journal:  Cancer Cell       Date:  2020-02-10       Impact factor: 31.743

3.  Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens.

Authors:  Fiona M Behan; Francesco Iorio; Gabriele Picco; Kosuke Yusa; Mathew J Garnett; Emanuel Gonçalves; Charlotte M Beaver; Giorgia Migliardi; Rita Santos; Yanhua Rao; Francesco Sassi; Marika Pinnelli; Rizwan Ansari; Sarah Harper; David Adam Jackson; Rebecca McRae; Rachel Pooley; Piers Wilkinson; Dieudonne van der Meer; David Dow; Carolyn Buser-Doepner; Andrea Bertotti; Livio Trusolino; Euan A Stronach; Julio Saez-Rodriguez
Journal:  Nature       Date:  2019-04-10       Impact factor: 49.962

4.  Genomic analyses of the metastasis-derived prostate cancer cell lines LNCaP, VCaP, and PC3-AR.

Authors:  Karolina Sienkiewicz; Chunsong Yang; Bryce M Paschal; Aakrosh Ratan
Journal:  Prostate       Date:  2021-12-24       Impact factor: 4.104

5.  Widespread Post-transcriptional Attenuation of Genomic Copy-Number Variation in Cancer.

Authors:  Emanuel Gonçalves; Athanassios Fragoulis; Luz Garcia-Alonso; Thorsten Cramer; Julio Saez-Rodriguez; Pedro Beltrao
Journal:  Cell Syst       Date:  2017-10-11       Impact factor: 10.304

6.  Open Targets Platform: new developments and updates two years on.

Authors:  Denise Carvalho-Silva; Andrea Pierleoni; Miguel Pignatelli; ChuangKee Ong; Luca Fumis; Nikiforos Karamanis; Miguel Carmona; Adam Faulconbridge; Andrew Hercules; Elaine McAuley; Alfredo Miranda; Gareth Peat; Michaela Spitzer; Jeffrey Barrett; David G Hulcoop; Eliseo Papa; Gautier Koscielny; Ian Dunham
Journal:  Nucleic Acids Res       Date:  2019-01-08       Impact factor: 16.971

7.  A human-based multi-gene signature enables quantitative drug repurposing for metabolic disease.

Authors:  James A Timmons; Andrew Anighoro; Robert J Brogan; Jack Stahl; Claes Wahlestedt; David Gordon Farquhar; Jake Taylor-King; Claude-Henry Volmar; William E Kraus; Stuart M Phillips
Journal:  Elife       Date:  2022-01-17       Impact factor: 8.713

8.  The somatic molecular evolution of cancer: Mutation, selection, and epistasis.

Authors:  Krishna Dasari; Jason A Somarelli; Sudhir Kumar; Jeffrey P Townsend
Journal:  Prog Biophys Mol Biol       Date:  2021-08-06       Impact factor: 4.799

9.  Using mechanistic models for the clinical interpretation of complex genomic variation.

Authors:  María Peña-Chilet; Marina Esteban-Medina; Matias M Falco; Kinza Rian; Marta R Hidalgo; Carlos Loucera; Joaquín Dopazo
Journal:  Sci Rep       Date:  2019-12-12       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.